Hybrid Seminar – CMC and Regulatory Strategies for Antibody Therapeutics (mAbs, BsAbs & TsAbs) Register now As antibody therapeutics continue to advance the next generation of biologics, developers face increasing challenges in process development, manufacturing, and regulatory compliance. Successfully navigating the journey from development to commercialization requires a well-integrated CMC and regulatory strategy to ensure product quality, scalability, and regulatory readiness. Join leading industry experts to gain practical insights, proven strategies, and real-world experience in overcoming these challenges and accelerate the path to commercialization. Event Details Topic: CMC and Regulatory Strategies for Antibody Therapeutics (mAbs, BsAbs & TsAbs) Date: August 27, 2026 Time: 17:30-20:00 Location: Online & Singapore Time Topic Speaker 17:30-17:45 Registration 17:45-18:00 Presentation Under invitation 18:00-18:20 Bispecific CMC Solutions for Chain Mispairing, Aggregation, and Beyond Ge Yan, Head of Antibody Upstream Process Development Dept., ProBio 18:20-18:35 Regulatory Affairs Insights for Antibody Therapeutics Dr. Esther WoonSenior Regulatory Specialist, Innovation Office and Clinical Trials Branch, HSA 18:35-19:05 Panel Discussion and Q&A Session 19:05-20:00 Networking with Buffet Related service: Fast Gram-scale Antibody Production Cell Line Development IND-enabling CMC Available materials « Previous Page ProBio Announces New Executive Appointments Next Page ProBio Accelerates Chimagen's Global Market Expansion, Paving the Way for Innovative Antibody Therapy » Contact us Phone: 1-877-436-7274 (Toll-Free); 1-732-885-9188 Fax: 1-732-210-0262
Latest WebinarsHybrid Seminar – CMC and Regulatory Strategies for Antibody Therapeutics (mAbs, BsAbs & TsAbs)Webinar – Reduce Risk in VHH and BsAb Discovery with Early Immunogenicity AssessmentAccelerating In Vivo CAR-T Antibody Discovery and DevelopmentsdAb Discovery & ExpressCMC™ with Cell Line Development WebinarFind More Therapeutic Antibody Categories